KAILERA THERAPEUTICS INC (KLRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$12.17-4.92%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · KLRA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Third Quarter Business Highlights and Recent Developments Pipeline Highlights Ribupatide Injection (KAI-9531), GLP-1/GIP Receptor Dual Agonist • KaiNETIC Global Phase 3 program in obesity fully enrol…
Stated in 3 of 3 supplied quarters. Management reported: “Third Quarter Business Highlights and Recent Developments Pipeline Highlights Ribupatide Injection (KAI-9531), GLP-1/GIP Receptor Dual Agonist • KaiNETIC Global Phase 3 program in obesity fully enrolled with data anticipated mid-2028: The program encompasses three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, NCT07284875; KaiNETIC-2, NCT07284901; KaiNETIC-3, NCT07284979) enrolling approximately 5,000 participants.” “• Phase 2b high dose clinical trial in obesity fully enrolled with data anticipated mid-2027: The double-blind, randomized, placebo-controlled Phase 2b trial (NCT07458269) enrolled approximately 260 participants in the U.S. with a BMI of 35 or greater without type 2 diabetes (T2D).”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
Not enough signal yet.
Not investment advice. As of 2026-11-05.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Third Quarter Business Highlights and Recent Developments Pipeline Highlights Ribupatide Injection (KAI-9531), GLP-1/GIP Receptor Dual Agonist • KaiNETIC Global Phase 3 program in obesity fully enrol…”
“Second Quarter Business Highlights and Recent Developments Pipeline Highlights Ribupatide Injection (KAI-9531), GLP-1/GIP Receptor Dual Agonist • Enrollment on track in global Phase 3 KaiNETIC progra…”
“First Quarter Business Highlights and Recent Developments Pipeline Highlights • Ribupatide injection (KAI-9531), GLP-1/GIP receptor dual agonist: o Initiated global Phase 3 KaiNETIC program: The prog…”
Ribupatide Oral (KAI-9531-T), GLP-1/GIP Receptor Dual Agonist • Completed End-of-Phase 2 meeting with U.S. FDA: Following the End-of-Phase 2 meeting, Kailera expects to initiate a global Phase 3 prog…
Stated in 3 of 3 supplied quarters. Management reported: “Ribupatide Oral (KAI-9531-T), GLP-1/GIP Receptor Dual Agonist • Completed End-of-Phase 2 meeting with U.S. FDA: Following the End-of-Phase 2 meeting, Kailera expects to initiate a global Phase 3 program in obesity in the first half of 2027.” “The Phase 3 program will include two trials evaluating once-daily ribupatide oral doses up to 25 mg over 60 weeks in adults living with obesity or overweight with comorbidities, with and without T2D.”
“Ribupatide Oral (KAI-9531-T), GLP-1/GIP Receptor Dual Agonist • Completed End-of-Phase 2 meeting with U.S. FDA: Following the End-of-Phase 2 meeting, Kailera expects to initiate a global Phase 3 prog…”
“Ribupatide Oral (KAI-9531-T), GLP-1/GIP Receptor Dual Agonist • Investigational New Drug (IND) application active with U.S. FDA: With an active IND, Kailera remains on track to initiate planned globa…”
“o Subject to discussions with the FDA and other regulatory agencies, Kailera plans to initiate Phase 3 global trials as early as the first half of 2027.”
Safiglipron (KAI-7535), Oral Small Molecule GLP-1 Receptor Agonist • Global Phase 2 trial in obesity fully enrolled with data now anticipated in mid-2027: The double-blind, randomized, placebo-contro…
Stated in 3 of 3 supplied quarters. Management reported: “Safiglipron (KAI-7535), Oral Small Molecule GLP-1 Receptor Agonist • Global Phase 2 trial in obesity fully enrolled with data now anticipated in mid-2027: The double-blind, randomized, placebo-controlled Phase 2 trial (NCT07497880) enrolled approximately 300 adult participants in the U.S. and Australia with a BMI of 30 or greater or a BMI of 27 or greater with at least one co-morbidity, which may include T2D.” “Data are anticipated in mid-2027.”
“Safiglipron (KAI-7535), Oral Small Molecule GLP-1 Receptor Agonist • Global Phase 2 trial in obesity fully enrolled with data now anticipated in mid-2027: The double-blind, randomized, placebo-contro…”
“KAI-7535, Oral Small Molecule GLP-1 Receptor Agonist • Phase 2 trial in obesity ongoing to further optimize KAI-7535's clinical profile: Kailera’s global Phase 2 trial is a multicenter, randomized, d…”
“• KAI-7535, oral small molecule GLP-1 receptor agonist: o Initiated global Phase 2 obesity trial: The double-blind, randomized, placebo-controlled trial is expected to enroll approximately 320 partic…”
KAI-4729, Injectable GLP-1/GIP/Glucagon Receptor Tri-Agonist • Investigational New Drug (IND) application active with U.S. FDA: With an active IND, Kailera is on track to initiate its Phase 1 single-…
Stated in 3 of 3 supplied quarters. Management reported: “KAI-4729, Injectable GLP-1/GIP/Glucagon Receptor Tri-Agonist • Investigational New Drug (IND) application active with U.S. FDA: With an active IND, Kailera is on track to initiate its Phase 1 single-dose injection site/ethnic bridging trial by the end of 2026, with data anticipated in 2027.”
“KAI-4729, Injectable GLP-1/GIP/Glucagon Receptor Tri-Agonist • Investigational New Drug (IND) application active with U.S. FDA: With an active IND, Kailera is on track to initiate its Phase 1 single-…”
“KAI-4729, Injectable GLP-1/GIP/glucagon Receptor Tri-Agonist • On track to begin global clinical development: Kailera remains on track to begin a Phase 1 trial in 2026 with data anticipated in 2027.”
“▪ Hengrui plans to advance HRS-4729 to Phase 2 clinical trials including for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH) in China, and Kailera plans to initia…”
R&D expenses were $84.7 million for the quarter ended September 30, 2026, compared to $27.0 million for the same period in 2025.
Stated in 3 of 3 supplied quarters. Management reported: “R&D expenses were $84.7 million for the quarter ended September 30, 2026, compared to $27.0 million for the same period in 2025.” “Net loss was $95.7 million for the quarter ended September 30, 2026, compared to a net loss of $39.6 million for the same period in 2025.”
“R&D expenses were $84.7 million for the quarter ended September 30, 2026, compared to $27.0 million for the same period in 2025.”
“Anticipated Key Milestones • Ribupatide injection: U.S. Phase 2b high dose obesity data anticipated in mid-2027; global Phase 3 obesity data anticipated in 2028 • Ribupatide oral: Global Phase 3 obes…”
“Anticipated Key Milestones • Ribupatide injection: U.S. Phase 2b high dose obesity data anticipated in 2027; global Phase 3 obesity data anticipated in 2028 • Ribupatide oral: Initiate global Phase 3…”